Skin Cancer Treatment in India
Get Skin Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Skin Cancer Treatment in UAE
Skin Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Skin cancer treatment encompasses a spectrum of evidence-based interventions — from Mohs micrographic surgery and wide local excision to immunotherapy, targeted therapy, and radiation oncology — achieving 5-year survival rates exceeding 98% for early-stage melanoma and non-melanoma subtypes when diagnosed promptly. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centers in India and JCI- and DHA-licensed hospitals in Dubai and Abu Dhabi, offering world-class dermatologic oncology at a fraction of Western costs. With dedicated case management from first consultation through post-treatment surveillance, GAF Healthcare ensures seamless, medically supervised care for every stage of the skin cancer journey.
Hospital Stay: 2–7 days (varies by treatment modality; Mohs surgery is often outpatient, while immunotherapy initiation or reconstructive surgery may require 3–7 days inpatient) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (surgical patients: typically 2–3 weeks post-op; systemic therapy (immunotherapy/targeted therapy) patients: 4–6 weeks to establish tolerance and confirm response before long-haul travel) • Success Rate: 95–99% (Stage I–II non-melanoma skin cancers); 85–92% (Stage I–II melanoma); 60–75% (Stage III melanoma with combined modality therapy)
What Is It?
Skin cancer arises from the uncontrolled proliferation of cutaneous cells, with three predominant histological subtypes: basal cell carcinoma (BCC), the most common malignancy worldwide; squamous cell carcinoma (SCC), which carries meaningful metastatic risk if neglected; and melanoma, the most aggressive form, originating from melanocytes and capable of rapid lymphatic and hematogenous spread. Additional rarer entities — Merkel cell carcinoma, dermatofibrosarcoma protuberans (DFSP), and cutaneous lymphomas — require subspecialty oncologic expertise. The physiological impact of advanced skin cancer extends well beyond the dermis: melanoma in particular exhibits a propensity to metastasize to regional lymph nodes, liver, lung, brain, and bone, triggering systemic inflammatory cascades and significant morbidity. SCC in immunocompromised patients (post-transplant recipients, HIV-positive individuals) can behave with near-melanoma aggression, necessitating vigilant multidisciplinary review.
The global standard of care is governed by NCCN (National Comprehensive Cancer Network) and ESMO guidelines, stratifying management by histological subtype, tumor depth (Breslow thickness for melanoma; Clark level), perineural invasion status, margin involvement, and lymphovascular invasion. For localized BCC and SCC, Mohs micrographic surgery remains the gold standard, offering the highest cure rates (up to 99% for primary BCC) with maximal tissue conservation — a critical consideration for cosmetically sensitive sites such as the face, ears, and periorbital regions. Melanoma management is stage-driven: sentinel lymph node biopsy (SLNB) is indicated for tumors ≥0.8 mm Breslow thickness; complete lymph node dissection (CLND) or nodal observation follows based on SLNB results. Adjuvant and metastatic melanoma treatment has been revolutionized by immune checkpoint inhibitors (anti-PD-1: pembrolizumab, nivolumab; anti-CTLA-4: ipilimumab) and BRAF/MEK-targeted agents (vemurafenib/cobimetinib; dabrafenib/trametinib for BRAF V600E/K-mutant disease), achieving durable responses that were unimaginable a decade ago.
Both India and the UAE have invested substantially in oncology infrastructure. Leading Indian cancer centers deploy Varian TrueBeam and Elekta linear accelerators for stereotactic radiosurgery, robotic-assisted lymph node dissection platforms, and in-house molecular pathology laboratories capable of BRAF, NRAS, c-KIT, and PD-L1 expression profiling. UAE facilities in Dubai Healthcare City (DHCC) and Abu Dhabi leverage the same technology alongside proximity to European and North American oncology networks, offering internationally credentialed tumor board consultations and clinical trial access.
Candidates
• ELIGIBLE PATIENTS:
• Histologically confirmed skin cancer (BCC, SCC, melanoma, Merkel cell carcinoma, DFSP, cutaneous T-cell lymphoma) at any stage, from in situ to Stage IV requiring systemic therapy
• Patients with recurrent or incompletely excised primary tumors seeking definitive re-excision or Mohs surgery
• Melanoma patients requiring sentinel lymph node biopsy (SLNB), completion lymph node dissection (CLND), or isolated limb perfusion (ILP) for regionally advanced disease
• Patients with BRAF V600E/K-mutant melanoma (confirmed by molecular profiling) eligible for targeted therapy (dabrafenib + trametinib; vemurafenib + cobimetinib)
• Patients with PD-L1-expressing or high tumor mutational burden (TMB-H) tumors suitable for anti-PD-1 immunotherapy (pembrolizumab, nivolumab)
• Patients requiring reconstructive surgery (local flaps, skin grafts, free tissue transfer) following oncologic excision
• Patients seeking adjuvant radiation therapy post-excision for high-risk SCC or melanoma with positive nodes
• REQUIRED PRE-TREATMENT DIAGNOSTICS:
• Full-thickness incisional or excisional skin biopsy with histopathology (H&E staining; immunohistochemistry for SOX10, S100, HMB-45, Melan-A for melanoma)
• Molecular profiling panel: BRAF V600E/K, NRAS, c-KIT mutation analysis; PD-L1 expression (22C3 pharmDx assay); TMB assessment via next-generation sequencing (NGS)
• Dermoscopy and, where indicated, reflectance confocal microscopy (RCM) for pre-biopsy lesion characterization
• Regional lymph node ultrasound ± fine needle aspiration cytology (FNAC)
• Whole-body PET-CT (FDG) for Stage IIB+ melanoma and high-risk SCC to exclude occult nodal or distant metastases
• MRI brain with gadolinium contrast for Stage III–IV melanoma (baseline and surveillance)
• CT chest/abdomen/pelvis with contrast for staging of regional and metastatic disease
• LDH (lactate dehydrogenase) — an independent prognostic biomarker in metastatic melanoma
• CBC, comprehensive metabolic panel, thyroid function tests (baseline for immunotherapy), and hepatitis B/C/HIV serology
• ECOG Performance Status assessment and dermatology/oncology multidisciplinary tumor board review
• CONTRAINDICATIONS / RELATIVE CONTRAINDICATIONS:
• Severe autoimmune disease (active Crohn's disease, SLE, autoimmune hepatitis) — relative contraindication to anti-PD-1/CTLA-4 immunotherapy due to immune-related adverse event (irAE) risk
• Active systemic infection or uncontrolled sepsis precluding surgery or immunosuppressive-adjacent therapy
• ECOG Performance Status ≥3 for high-intensity systemic regimens; palliative intent should be discussed
• Prior severe hypersensitivity to checkpoint inhibitors or BRAF/MEK inhibitors without rechallenge protocol in place
• Organ transplant recipients on calcineurin inhibitors — immunotherapy carries substantial rejection risk; specialist transplant-oncology co-management required
• Pregnancy (relative contraindication for systemic targeted/immune therapy; surgery generally permissible with obstetric co-management)
Procedure
SURGICAL APPROACHES:
1. Mohs Micrographic Surgery (MMS): The oncologic gold standard for high-risk BCC and SCC in cosmetically or functionally critical anatomic sites (H-zone of the face, ears, nose, eyelids, lips, genitalia, hands, feet). The procedure involves sequential horizontal tissue excision with immediate intraoperative frozen-section margin analysis — processing 100% of the peripheral and deep surgical margins (versus the 1–2% sampled by bread-loafing in standard excision). Each stage is mapped, color-coded, and processed in a cryostat on-site. Cure rates: 99% for primary BCC, 97% for recurrent BCC, 95–97% for primary SCC. Typically performed under local anesthesia as a same-day outpatient procedure.
2. Wide Local Excision (WLE): Standard surgical approach for melanoma, with margins defined by Breslow thickness per NCCN guidelines (in situ: 0.5–1 cm; ≤1 mm: 1 cm; 1.01–2 mm: 1–2 cm; >2 mm: 2 cm). Performed under local or general anesthesia depending on lesion size and location; may require reconstructive closure with primary repair, split-thickness skin grafting (STSG), or local advancement/rotation/transposition flaps.
3. Sentinel Lymph Node Biopsy (SLNB): Indicated for melanoma ≥0.8 mm Breslow thickness (or ≥0.6 mm with adverse features: ulceration, mitotic rate ≥2/mm², lymphovascular invasion). Technetium-99m nanocolloid lymphoscintigraphy maps the sentinel node basin pre-operatively; intraoperative gamma probe + isosulfan blue/Patent Blue dye identifies the sentinel node(s) for excision. Pathological assessment by step-serial sectioning with H&E and S100/HMB-45 IHC. SLNB provides critical prognostic staging and guides adjuvant therapy decisions.
4. Completion Lymph Node Dissection (CLND) / Therapeutic Lymph Node Dissection (TLND): CLND (dissection of the entire regional nodal basin following a positive SLNB) has evolved in practice following the MSLT-II trial, which demonstrated that observation with ultrasound surveillance is non-inferior to routine CLND for disease-specific survival in many patients. TLND remains standard for clinically palpable nodal disease.
5. Isolated Limb Perfusion (ILP) / Isolated Limb Infusion (ILI): Used for in-transit melanoma metastases or unresectable regionally advanced extremity SCC. ILP employs extracorporeal perfusion of the affected limb with hyperthermic (38–40°C) melphalan ± tumor necrosis factor-alpha (TNF-α), achieving high regional drug concentrations with systemic isolation via tourniquet. Complete response rates of 40–80% reported.
6. Robotic-Assisted Surgery: Minimally invasive robotic platforms (da Vinci Surgical System) are increasingly utilized for deep cervical lymph node dissections, parotidectomy in head-and-neck SCC, and reconstructive microsurgery, offering enhanced dexterity, tremor filtration, and 3D magnification in anatomically confined dissection planes.
RADIATION THERAPY:
7. External Beam Radiotherapy (EBRT): Definitive or adjuvant radiotherapy for non-surgical candidates or high-risk SCC/BCC with perineural invasion, bone involvement, or positive/close margins. Modern delivery via IMRT (Intensity-Modulated Radiation Therapy) or VMAT (Volumetric Modulated Arc Therapy) using Varian TrueBeam or Elekta Versa HD linacs, enabling precise dose sculpting to minimize salivary gland, ocular, and neural toxicity.
8. Stereotactic Radiosurgery (SRS) / Stereotactic Body Radiotherapy (SBRT): For oligometastatic melanoma brain metastases, Gamma Knife (Leksell) or CyberKnife delivers ablative-dose radiation (15–24 Gy in 1–5 fractions) with sub-millimeter accuracy, frequently replacing whole-brain radiotherapy and preserving neurocognitive function.
9. Superficial/Orthovoltage Radiotherapy & Brachytherapy: For elderly patients or those who refuse surgery, superficial X-ray therapy or HDR brachytherapy (mold technique) offers effective local control for small BCC/SCC with acceptable cosmesis.
SYSTEMIC & TARGETED THERAPIES:
10. Immune Checkpoint Inhibitors (ICI):
• Anti-PD-1 monotherapy: Pembrolizumab (KEYTRUDA®, 200 mg IV Q3W or 400 mg Q6W) and nivolumab (OPDIVO®, 240 mg Q2W or 480 mg Q4W) — first-line for unresectable/metastatic melanoma and high-risk adjuvant melanoma; also approved for advanced Merkel cell carcinoma (avelumab, pembrolizumab) and advanced SCC (cemiplimab, pembrolizumab)
• Combination ICI: Nivolumab + ipilimumab (CheckMate 067 regimen) for metastatic melanoma — superior PFS and OS vs. monotherapy, at the cost of higher irAE rates (~55% Grade 3–4)
• Relatlimab + nivolumab (OPDUALAG®): Novel LAG-3/PD-1 dual blockade approved for unresectable/metastatic melanoma, demonstrating improved PFS over nivolumab alone in RELATIVITY-047
11. BRAF/MEK-Targeted Therapy (for BRAF V600-mutant melanoma, ~50% of cutaneous melanomas):
• Dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor): COMBI-d/v trials — 64% ORR, median PFS ~11 months; also approved in adjuvant setting (COMBI-AD trial)
• Vemurafenib + cobimetinib; encorafenib + binimetinib (COLUMBUS trial — longest PFS in BRAF-targeted therapy class)
12. Hedgehog Pathway Inhibitors (for advanced/metastatic BCC):
• Vismodegib (ERIVEDGE®) and sonidegib (ODOMZO®): SMO inhibitors blocking aberrant Hedgehog signaling — first-line for locally advanced unresectable or metastatic BCC; ORR ~43–60% for locally advanced disease
13. EGFR Inhibitors & Chemotherapy:
• Cetuximab (anti-EGFR monoclonal antibody) for advanced/metastatic SCC in platinum-ineligible patients
• Conventional cytotoxic chemotherapy (carboplatin, paclitaxel, dacarbazine) reserved for ICI/targeted therapy-refractory disease
14. Electrochemotherapy (ECT): Combination of IV or intratumoral bleomycin with short high-voltage electrical pulses (electroporation) to enhance intracellular drug uptake — highly effective palliative option for skin-surface melanoma/SCC metastases not amenable to surgery
PHOTODYNAMIC THERAPY (PDT) & TOPICAL THERAPIES:
• PDT with aminolevulinic acid (ALA) or methyl-aminolevulinate (MAL) cream + red light activation: First-line for superficial BCC, Bowen's disease (SCC in situ), and actinic keratoses; excellent cosmesis, suitable for field cancerization
• Topical imiquimod (Aldara®, 5%) — Toll-like receptor 7 agonist; approved for superficial BCC and actinic keratoses
• Topical 5-fluorouracil (Efudex®, 5%): For actinic keratoses and superficial BCC
Cost of Skin Cancer Treatment: India vs. UAE
The cost of skin cancer treatment varies substantially based on histological subtype, stage, chosen modality (surgery alone, surgery plus immunotherapy, targeted therapy, or radiation), and the destination country. India offers exceptional oncologic expertise at 50–65% lower cost than the UAE, while the UAE provides a premium, Western-equivalent care environment with luxury infrastructure and direct flight access from the GCC, Europe, and Africa. Both destinations offer JCI-accredited facilities with internationally trained dermatologic oncologists and access to the same FDA/EMA-approved drug portfolio. The ranges below reflect comprehensive treatment costs for the most common clinical scenarios — from Mohs surgery for localized BCC/SCC through to multi-cycle immunotherapy for advanced melanoma.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $2,500 – $28,000 | ~53% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $5,500 – $60,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–2 before travel):
• Patient submits existing biopsy reports, dermoscopy images, histopathology slides (digitized), and imaging (PET-CT, MRI, CT) to GAF Healthcare's oncology case management team
• GAF Healthcare facilitates asynchronous tumor board review by destination hospital's dermatologic oncology MDT (multidisciplinary team), with formal treatment recommendation issued within 48–72 hours
• Molecular pathology review: BRAF/NRAS/c-KIT mutation status and PD-L1 expression confirmed; if profiling is incomplete, GAF arranges sample re-testing at destination laboratory
• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry documentation; medical invitation letter issued by treating hospital
• Pre-travel checklist issued: medications to pause (anticoagulants, immunosuppressants, biologics with washout requirements), baseline blood tests to obtain locally, and fitness-to-travel clearance if needed
PHASE 2 — ARRIVAL & BASELINE ASSESSMENT (Days 1–3):
• Airport transfer arranged by GAF concierge; hotel/hospital accommodation confirmed for patient and attendant
• Day 1: Registration, dedicated GAF patient coordinator assigned; hospital orientation and language interpreter engaged
• Day 1–2: Repeat/confirmatory staging workup if required — dermoscopy, whole-body PET-CT, MRI brain (melanoma), LDH, CBC, metabolic panel, thyroid function tests (for immunotherapy candidates), ECG, anesthesia pre-assessment
• Day 2–3: Formal oncology consultation; surgical and/or medical oncology review; consent process with GAF interpreter present; surgical site marking and lymphoscintigraphy mapping (if SLNB planned)
PHASE 3 — SURGICAL INTERVENTION (Day 3–5, depending on staging workup timeline):
• Mohs Surgery (outpatient): Procedure commences under local anesthesia; each Mohs stage takes approximately 45–60 minutes for processing; typical cases complete in 2–4 stages (3–6 hours total); same-day reconstructive closure; patient discharged same day
• Wide Local Excision ± SLNB (Day Surgery / 1–2 nights): General or regional anesthesia; gamma probe-guided sentinel node identification; WLE with pre-planned margins; intraoperative frozen section if margin concern; reconstructive closure; drain placement if required; hospital stay 1–2 nights
• Lymph Node Dissection / ILP (3–5 nights): More extensive procedure under general anesthesia; regional dissection (axillary, inguinal, cervical); drains in situ 3–5 days; patient mobilized Day 1 post-op
• Robotic-assisted cervical or inguinal dissection: Similar stay; enhanced visualization, reduced blood loss vs. open technique
PHASE 4 — INPATIENT RECOVERY & COMPLICATION SURVEILLANCE (Days 5–10 post-op):
• Wound care protocol: daily nursing assessment, drain output monitoring, compression garment fitting for lymphedema prevention
• Pathology results turnaround: Final histopathology (permanent sections) available 5–7 business days post-surgery; margin status, mitotic rate, lymph node involvement confirmed
• MDT reconvenes to finalize adjuvant therapy plan: Adjuvant immunotherapy (pembrolizumab ×1 year post-resection per KEYNOTE-054), adjuvant targeted therapy (dabrafenib+trametinib ×1 year per COMBI-AD), or adjuvant radiotherapy as indicated
• Suture/staple removal at Day 7–14 depending on wound site and tension
PHASE 5 — INITIATION OF SYSTEMIC THERAPY (if applicable, Weeks 2–6):
• Immunotherapy Cycle 1 administered in destination hospital under direct supervision; 6-hour observation post-infusion for infusion-related reactions
• Toxicity monitoring: LFTs, thyroid function, cortisol (pituitary function), creatinine, CBC at Day 7 and Day 14 post-infusion
• Targeted therapy (dabrafenib+trametinib) initiated as outpatient; baseline ophthalmology assessment (uveitis risk), cardiac assessment (QTc prolongation), and dermatology review (paradoxical keratoacanthoma risk)
• BRAF/MEK-targeted therapy patients typically tolerant within 2–4 weeks; pyrexia (dabrafenib class effect) managed with dose interruption and paracetamol
PHASE 6 — FIT-TO-FLY ASSESSMENT & DISCHARGE PLANNING (Weeks 3–6):
• Surgical-only patients (Mohs, WLE without systemic therapy): Fit-to-fly typically at 2–3 weeks post-op, subject to wound healing confirmation and absence of infection or hematoma
• Systemic therapy patients: Fit-to-fly at 4–6 weeks, after Cycle 1 toxicity has been assessed, first response evaluation completed, and home country oncologist formally briefed with a comprehensive discharge summary
• GAF Healthcare coordinates: full medical records package (digital + hard copy), radiology image CD/USB, molecular pathology reports, systemic therapy continuation prescriptions with international drug availability guidance, and next surveillance imaging schedule (PET-CT/MRI at 3-month intervals)
• Return airport transfer and travel insurance documentation prepared
PHASE 7 — REMOTE FOLLOW-UP WITH GAF HEALTHCARE:
• GAF's telemedicine platform enables monthly virtual check-ins with destination oncologist for the first 6 months
• irAE (immune-related adverse event) alert protocol: patient educated to report new onset rash, diarrhea, dyspnea, visual changes, or neurological symptoms immediately via GAF 24/7 WhatsApp oncology helpline
• Annual surveillance imaging and skin examination reminders managed by GAF case coordinator
Risks & Considerations
Skin cancer treatment is generally well-tolerated when appropriately matched to tumor biology and patient fitness, but carries specific, clinically meaningful risks that patients must understand before traveling for care. Surgical risks include wound infection (2–5% for standard excision; lower for Mohs due to outpatient aseptic technique), wound dehiscence, hematoma or seroma formation (particularly after lymph node dissection), and lymphedema — a chronic, potentially disabling complication occurring in 10–40% of patients after inguinal or axillary nodal dissection, requiring lifelong compression garment use. Nerve injury is a relevant risk for cervical dissection (spinal accessory nerve — shoulder drop; marginal mandibular branch of facial nerve — lip asymmetry) and inguinal dissection (femoral nerve, lateral femoral cutaneous nerve). Cosmetic outcomes after facial Mohs surgery are generally excellent with experienced reconstruction, but scarring, pin-cushioning of flaps, or pigmentation mismatch in skin grafts may require revision procedures.
Immunotherapy-specific risks (immune-related adverse events, irAEs) are the most clinically significant consideration for systemic therapy candidates. Checkpoint inhibitors can trigger autoimmune inflammation in virtually any organ system: immune-mediated dermatitis (30–40%), colitis (10–15%, potentially severe), hepatitis (5–10%), pneumonitis (3–5%), endocrinopathies — thyroiditis (20–30%), adrenal insufficiency (1–2%), hypophysitis (1–3%) — and rarer but serious neurological (Guillain-Barré, myasthenia gravis) and cardiac (myocarditis, <1% but mortality rate ~25–50% if untreated) events. High-grade irAEs require immediate corticosteroid therapy (methylprednisolone 1–2 mg/kg/day IV) and immunotherapy discontinuation; specialist oncology access during the fit-to-fly window is therefore mandatory. Combination nivolumab + ipilimumab carries Grade 3–4 irAE rates of approximately 55%, necessitating closer monitoring. Patients traveling for immunotherapy must have an established emergency oncology contact in their home country and must not book return flights before Cycle 1 toxicity has fully been assessed.
Top Hospitals for Skin Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Skin Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Frequently Asked Questions — Skin Cancer Treatment
The total cost of skin cancer treatment depends heavily on the stage of disease, the histological subtype (BCC, SCC, melanoma), and the treatment modality required. In India, costs typically range from USD 2,500 to USD 28,000: Mohs micrographic surgery for localized BCC or SCC generally costs USD 2,500–5,500; wide local excision with sentinel lymph node biopsy for early-stage melanoma runs USD 4,000–8,000; and a combined surgical plus multi-cycle immunotherapy package (e.g., pembrolizumab adjuvant therapy) or BRAF/MEK-targeted therapy for advanced melanoma can reach USD 15,000–28,000 per treatment episode. In the UAE (Dubai or Abu Dhabi), equivalent procedures cost approximately USD 5,500 to USD 60,000 — roughly 2–2.5× higher than India — reflecting the premium hospital infrastructure, luxury private room standards, and the higher cost base of operating in the GCC healthcare market. Critically, both destinations deploy the same FDA- and EMA-approved drugs (pembrolizumab, nivolumab, dabrafenib, trametinib, vismodegib) and the same oncology technology platforms (Varian TrueBeam linacs, robotic surgery, NGS molecular profiling), meaning the clinical standard of care is equivalent. India is generally recommended for patients prioritizing cost efficiency, while the UAE is preferred by GCC residents, patients requiring shorter travel distances, or those seeking a Western-equivalent luxury care environment. GAF Healthcare provides transparent, itemized cost estimates for your specific case before any commitment is required.
The fit-to-fly duration is determined by your treatment modality and individual clinical response, and should not be compressed for convenience without oncologist clearance. For patients undergoing Mohs micrographic surgery or simple wide local excision without systemic therapy, a minimum stay of 2–3 weeks post-procedure is recommended. This window allows confirmation of wound healing, removal of sutures or staples (typically Day 7–14), review of final histopathology results (available 5–7 business days post-surgery), and receipt of the adjuvant therapy plan. Long-haul flights carry a meaningful deep vein thrombosis (DVT) risk in post-surgical patients, and cabin pressure changes can affect wound healing and edema, making premature departure inadvisable. For patients undergoing sentinel lymph node biopsy or lymph node dissection, the same 2–3 week minimum applies, with additional time if drains remain in situ or if lymphedema management is being established. For patients initiating immunotherapy (anti-PD-1 or combination ICI regimens), a minimum stay of 4–6 weeks is required: this encompasses Cycle 1 administration, 14-day toxicity monitoring (immune-related adverse events — including hepatitis, colitis, and pneumonitis — can manifest 2–4 weeks post-infusion), and confirmation that your home-country oncologist has received the full treatment summary and is equipped to manage continuation therapy and irAE emergencies. For patients on BRAF/MEK-targeted therapy (oral agents), 4 weeks in-country allows assessment of the febrile pyrexia response (dabrafenib class effect), first pharmacokinetic steady-state, and first radiological response evaluation. GAF Healthcare issues a formal Fit-to-Fly Certificate signed by your treating oncologist before you depart, and your return flights are booked with full travel insurance covering medical repatriation.
Success rates for skin cancer treatment are among the highest in oncology when disease is detected and treated at early stages, but vary significantly by histological subtype and disease extent. For non-melanoma skin cancers treated with Mohs micrographic surgery: 5-year cure rates reach 98–99% for primary basal cell carcinoma (BCC) and 95–97% for primary squamous cell carcinoma (SCC) at cosmetically sensitive sites. For high-risk SCC with perineural invasion or nodal involvement, 5-year disease-specific survival drops to 70–85%, underscoring the importance of multidisciplinary adjuvant management. For cutaneous melanoma, outcomes are strongly stage-dependent per AJCC 8th Edition staging: Stage I (thin, node-negative melanoma, Breslow ≤1 mm): 5-year overall survival 97–99%; Stage II (thicker, node-negative): 80–94% depending on ulceration and mitotic rate; Stage III (regional nodal metastasis): 5-year OS of 40–78%, dramatically improved by adjuvant pembrolizumab (KEYNOTE-054: 75.4% recurrence-free survival at 3.5 years vs. 61.4% placebo) or adjuvant dabrafenib+trametinib (COMBI-AD: 54% relapse-free survival at 5 years vs. 38% placebo in BRAF V600-mutant disease); Stage IV (distant metastasis): historically <10% 5-year OS, now transformed by immunotherapy — CheckMate 067 (nivolumab + ipilimumab) demonstrates 52% 5-year OS in metastatic melanoma, and RELATIVITY-047 (relatlimab + nivolumab) shows further PFS improvement. For Merkel cell carcinoma, 5-year OS for localized disease is approximately 55–65%; avelumab and pembrolizumab have produced durable responses (ORR ~33–40%) in advanced/metastatic disease. GAF Healthcare's oncology partners in India and the UAE operate high-volume melanoma and skin oncology programs with outcomes benchmarked against international registries, and all cases are reviewed by tumor boards applying current NCCN and ESMO guideline standards.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides an end-to-end non-medical support infrastructure designed to eliminate logistical friction for international oncology patients and their families.
VISA & ENTRY DOCUMENTATION — INDIA: GAF Healthcare's visa assistance team prepares and submits the complete e-Medical Visa (e-MV) application package for India-bound patients, including the formal medical invitation letter from the treating JCI/NABH-accredited hospital, supporting oncology reports, and treatment cost estimates. India's e-Medical Visa is typically approved within 3–5 business days and permits a 60-day stay with up to three entries — adequate for surgical episodes plus initial systemic therapy cycles. Visas for two attendants (family caregivers) are processed simultaneously under India's e-Medical Attendant Visa category at no additional GAF service fee.
VISA & ENTRY DOCUMENTATION — UAE: The UAE offers visa-on-arrival or visa-free access for passport holders from over 50 countries (including the UK, EU Schengen zone, USA, Canada, and Australia). For GCC residents and nationals, no visa is required. Patients from other regions receive a 30- or 90-day tourist/visit visa facilitated through GAF Healthcare's UAE partner hospitals, which can issue medical NOC letters to support longer-stay visa extensions through the Dubai Health Authority (DHA) or Abu Dhabi Department of Health (DOH). All visa documentation is managed digitally with confirmation typically within 24–48 hours.
AIRPORT TRANSFERS & IN-COUNTRY TRANSPORT: Private airport-to-hospital transfers are pre-arranged for patients and attendants in both destinations, using wheelchair-accessible vehicles where required. All inter-facility transfers (e.g., hospital to radiotherapy center, or to a partner diagnostic imaging facility) are scheduled and coordinated by the GAF in-country concierge team, eliminating the need for patients to navigate local transport systems.
DEDICATED TRANSLATORS & CULTURAL LIAISONS: GAF Healthcare provides professional medical interpreters for Arabic, Russian, French, Swahili, Amharic, and other major languages at no additional cost for all clinical consultations, consent discussions, and discharge briefings. Cultural liaison officers are assigned to patients from GCC countries, East Africa, and Central Asia to ensure dietary, religious (Halal meal arrangements, prayer space access), and social preferences are accommodated throughout the hospital stay.
ACCOMMODATION FOR PATIENTS & ATTENDANTS: For surgical-only patients discharged to hotel-based recovery, GAF Healthcare maintains preferred-rate partnerships with medically suitable hotels within 5–10 minutes of treating hospitals in Mumbai, Delhi, Chennai, Hyderabad, Dubai, and Abu Dhabi — all pre-vetted for cleanliness, elevator access, proximity to pharmacies, and 24-hour reception. For patients undergoing multi-week systemic therapy, serviced apartment arrangements with kitchenette facilities are available, enabling attendants to prepare culturally appropriate meals. Hospital guest accommodation (attendant rooms or family suites) is pre-booked by GAF at JCI-accredited facilities that offer in-room attendant stays.
TELEMEDICINE & REMOTE MONITORING: GAF Healthcare's digital health platform enables pre-departure oncology consultations, real-time lab result sharing with treating oncologists, and post-departure virtual follow-ups. Patients are issued a GAF Health Passport — a secure digital document containing their full oncology records, treatment summary, molecular pathology results, and emergency contact protocols — accessible by any treating physician worldwide via a QR-coded secure link.
Patients Also Explore
Other treatments commonly sought by patients considering Skin Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology